Biotech entity
pharma is the sole category represented across all 3 tracked stories. Of the tracked stories, 2 of 3 also mention Johnson & Johnson, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline.
Last mentioned: Sep 8, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 3 tracked stories. Of the tracked stories, 2 of 3 also mention Johnson & Johnson, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline. That works out to roughly 0.1 stories per week across a 201-day span. Their average consequence score of 5.3 runs below the beat's 6.1 for that window. This profile follows 3 Biotech stories mentioning Takeda Pharmaceutical across the period from February 20, 2026 to September 8, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 758 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Takeda Pharmaceutical. Shared-story counts are live from our verified record — not editorial picks.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Protagonist's board authorized a $300 million repurchase, backed by $849.5 million in cash and royalty streams from two FDA-approved drugs. For biotech observers, the move marks a shift from cash burn to capital return as partnered products generate milestone and royalty income.
Source: finanznachrichten.de · Seeking Alpha
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
Takeda Pharmaceutical is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
